We observed a higher incidence of HER2 overexpression with 45% of cases being positive for HER2 compared with the 20% incidence of HER2 positivity seen in all patients with breast cancer, this is in agreement with previous reports which have analyzed HER2 as a risk factor for the development of BM 18,19. This evidence concerns the gene ERBB2 and breast cancer.